Elicio Therapeutics to Present Promising Clinical and Preclinical Data on Immunotherapies at AACR Annual Meeting
BOSTON, April 05, 2024 - Elicio Therapeutics, a pioneering biotechnology company focused on developing innovative immunotherapies for cancer treatment, has announced its participation in the prestigious American Association for Cancer Research (AACR) Annual Meeting in San Diego, California from April 5-10, 2024. The company will unveil updates on its pipeline of investigational candidates, including ELI-002, ELI-007, and ELI-008, showcasing potentially groundbreaking advancements in cancer immunotherapy.
The highlight of Elicio’s presentation will be the updated immunogenicity data from the ongoing Phase 1 (AMPLIFY-201) study of ELI-002. ELI-002 is an off-the-shelf therapeutic cancer vaccine specifically designed for patients with mutant Kirsten rat sarcoma (mKRAS)-driven pancreatic and colorectal cancers. The Phase 1 study aims to evaluate the vaccine’s efficacy, safety, and tolerability. By sharing updated clinical data, Elicio hopes to demonstrate the potential of ELI-002 as a revolutionary treatment for these challenging cancers.
In addition, Elicio will also be sharing preclinical data on ELI-007 and ELI-008, two cutting-edge investigational peptide vaccines. ELI-007 targets BRAF-driven cancers, while ELI-008 focuses on p53-driven cancers. These preclinical studies showcase Elicio’s commitment to developing highly specific and targeted immunotherapies that address the unique genetic characteristics of individual tumors.
Elicio’s participation in the AACR Annual Meeting reflects the company’s dedication to scientific excellence and its mission to transform cancer treatment through the power of immunotherapy. The company recognizes the importance of sharing up-to-date clinical and preclinical data with the global scientific community in order to foster collaboration and accelerate the development of effective cancer therapies.
We are excited to present our latest findings at the AACR Annual Meeting, said Dr. Jean Viallet, Chief Scientific Officer of Elicio Therapeutics. The data we will be sharing on ELI-002, ELI-007, and ELI-008 represents significant progress in the field of cancer immunotherapy. These innovative therapies have the potential to make a real difference in the lives of patients suffering from pancreatic, colorectal, BRAF-driven, and p53-driven cancers.
Elicio Therapeutics remains at the forefront of immunotherapy research and development, utilizing its novel Amphiphile technology platform to create potent therapeutic vaccines and immunotherapies. With a focus on targeting specific tumor antigens and inducing a robust T cell response, Elicio aims to harness the body’s own immune system to fight cancer, revolutionizing the treatment landscape.
As collective efforts continue to advance the field of immunotherapy, Elicio Therapeutics’ groundbreaking findings presented at the AACR Annual Meeting hold promise for patients and clinicians alike. By sharing its impressive clinical and preclinical data, Elicio takes a significant step towards transforming the outlook for cancer patients and propelling the field of immunotherapy towards new horizons.
Comments